Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β | Zendy

Bibiana Bielekova | Zendy; Nancy Richert | Zendy; T. Howard | Zendy; Gregg Blevins | Zendy; Silva MarkovicPlese | Zendy; Jennifer McCartin | Zendy; Jens Würfel | Zendy; Joan Ohayon | Zendy; Thomas A. Waldmann | Zendy; Henry F. McFarland | Zendy; Roland Martinꝉ | Zendy

Open Access

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Author(s) -

Bibiana Bielekova,

Nancy Richert,

T. Howard,

Gregg Blevins,

Silva MarkovicPlese,

Jennifer McCartin,

Jens Würfel,

Joan Ohayon,

Thomas A. Waldmann,

Henry F. McFarland,

Roland Martinꝉ

Publication year - 2004

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.0402653101

Subject(s) - daclizumab , multiple sclerosis , medicine , monoclonal antibody , clinical trial , interferon beta , disease , immunology , oncology , pharmacology , antibody

Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-beta therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research